ZC511.com
Innovative pharmaceutical trade platform offering licensed medicines and medical devices with strategic health collaborations
About ZC511.com
ZC511.com operates as a comprehensive pharmaceutical trade platform, specializing in the distribution of licensed medicines and medical devices. The company collaborates with key health institutions such as the National Health Management Board and the Zhejiang Health Board to ensure regulatory compliance and quality assurance. ZC511.com serves a diverse client base, including healthcare providers, pharmacies, and medical institutions, primarily within the Zhejiang Province. The business model revolves around leveraging strategic partnerships and regulatory certifications to facilitate the sale and distribution of pharmaceutical products. Revenue is generated through the sale of medicines and medical devices, supported by a robust licensing framework that includes certificates for the operation of type II medical devices and internet pharmaceutical trade services. The company’s market presence is bolstered by its commitment to quality and regulatory adherence, making it a trusted partner in the healthcare supply chain.
Source: Dealroom company dataAt a glance
- Founded
- 2002
- Headquarters
- Hangzhou, China
- Sector
- Hard Tech
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- SCSinopharm Capital
Series A2 investors entered at this stage
- SISinowisdom
- CPConba Pharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ZC511.com on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ZC511.com on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.